New AI Blood Test Offers Early Alzheimer’s Detection

Email: online@newsofbahrain.com 

A significant leap in neurological diagnostics has arrived with the launch of the first AI-integrated blood biomarker test for early Alzheimer’s detection in India. This newly introduced plasma test, which carries both USFDA and CDSCO approval, is designed to identify the biological hallmarks of Alzheimer’s pathology long before severe cognitive decline manifests. By shifting the diagnostic process from invasive cerebrospinal fluid procedures to a simple blood draw, the test provides a scalable solution to a growing global health challenge, aligning current diagnostic capabilities with international standards established in early 2025.

The introduction of this tool comes at a critical time as the prevalence of dementia continues to rise globally. Projections suggest that cases could nearly double over the next decade, driven largely by an ageing population. Traditional diagnostic methods, such as amyloid PET scans, have historically been cost-prohibitive and geographically limited, often leaving patients to be diagnosed only after symptoms have reached a debilitating stage. This new blood-based protocol acts as a primary gatekeeper, where positive or borderline results trigger further AI-enabled MRI brain imaging or FDG PET scans only when necessary, significantly lowering the barrier to entry for early intervention.

Clinical data highlights the test's impressive accuracy, boasting a 91.7% positive concordance and 97.3% negative concordance with traditional amyloid PET scans. Medical experts, including Prof. V.S. Mehta of Paras Health, have hailed the development as a cornerstone for effective care, noting that AI-driven biomarkers paired with advanced imaging allow for intervention while patients still retain significant cognitive function. The test is specifically targeted at individuals over 50 experiencing memory issues, those with mild cognitive impairment, or those with a family history of the disease.

The strategic rollout of this technology aims to redefine patient outcomes by empowering families to plan for the future sooner. Early detection opens the door to lifestyle modifications, specialised medications, and support systems that can slow the progression of the disease. As healthcare systems brace for an influx of dementia cases, the integration of lab-based blood tests with AI-assisted neurology represents a transformative shift toward accessible, high-fidelity diagnostic care.